Author

F. Rocamora

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Biochemistry· 1 Bioengineering· 1 Microbiology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 3 Approach:experimental assay· 2 Organism:human· 2 Organism:mouse· 2 Approach:genetic perturbation / CRISPR· 1 Assay:metabolomics· 1 Assay:protein sequence· 1 Organism:yeast· 1

Frequent Co-Authors

E. A. Winzeler· 2 shared G. M. LaMonte· 2 shared S. Ottilie· 2 shared A. F. Cowman· 1 shared A. J. O'Donoghue· 1 shared A. L. Cheung· 1 shared B. G. R. Voldborg· 1 shared B. Y. Zou· 1 shared

Activity by Year

2019-2024 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 31 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersBiochemistry

E. A. Winzeler

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Glycoengineered recombinant alpha1-antitrypsin results in comparable in vitro and in vivo activities to human plasma-derived protein

F. Rocamora, S. Schoffelen, J. Arnsdorf, E. A. Toth, Y. Abdul, T. E. Cleveland, S. P. Bjorn, M. Y. M. Wu, N. G. McElvaney, B. G. R. Voldborg, T. R. Fuerst, N. E. Lewis

This study generates glycoengineered recombinant alpha1-antitrypsin with in vitro and in vivo activities comparable to plasma-derived A1AT, offering a sustainable therapeutic alternative.

bioRxiv · Mar 27, 2024 · PreprintBioengineering

Development of Highly Selective Epoxyketone-based Plasmodium Proteasome Inhibitors with Negligible Cytotoxicity

J. Almaliti, P. Fajtova, J. Calla, G. M. LaMonte, M. Feng, F. Rocamora, S. Ottilie, E. Glukhov, E. Boura, R. T. Suhandynata, J. D. Momper, M. K. Gilson, E. A. Winzeler, W. H. Gerwick, A. J. O'Donoghue

This study develops highly selective epoxyketone-based proteasome inhibitors effective against Plasmodium falciparum with low cytotoxicity to human cells.

bioRxiv · Aug 6, 2022 · PreprintBiochemistry

Pan-active imidazolopiperazine antimalarials target the Plasmodium falciparum intracellular secretory pathway

G. M. LaMonte, D. S. Marapana, N. Gnadig, S. Ottilie, M. R. Luth, T. S. Worgall, F. Rocamora, G. M. Goldgof, R. Mohunlal, T. R. S. Kumar, J. K. Thompson, E. Vigil, J. Yang, D. Hutson, T. Johnson, , E. A. Winzeler

This study identifies imidazolopiperazines as targeting the Plasmodium falciparum secretory pathway by inhibiting protein trafficking and ER expansion.

bioRxiv · Aug 15, 2019Microbiology